A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)
ConditionHealthy
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19-55
SponsorMerck Sharp & Dohme LLC
About this trial
The goal of this trial is to learn what happens to different formulations (types) of enlicitide in a healthy person's body over time. Researchers will compare the amount of enlicitide in a healthy person's body over time when different formulations are given on an empty stomach and after a high-fat meal.
Eligibility criteria
Qualifiers
Is in good health
Has a body-mass index (BMI) between ≥18.0 and ≤32.0 kg/m²
Disqualifiers
Has history of gastrointestional (GI) disease which might affect food and drug absorption or has had gastric bypass or similar surgery. Examples of GI disease include (but are not limited to) recurrent vomiting, inflammatory bowel disease, chronic intestinal disease accompanied by a disturbance in digestion and absorption, Roemheld's syndrome, and severe hernia
Has a history of cancer (malignancy)
Has positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)
Is lactose intolerant
Trial design
Treatments tested in this trial
- Enlicitide
Treatment groups
30 Participants
are divided into 5 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov